Industry

BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Alnylam® Pharmaceuticals (Alnylam), which will enable Alnylam to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark … [Read more…]

HONG KONG–(BUSINESS WIRE)–Pacific Prime, an award-winning global health insurance brokerage and employee benefits specialist, has released the fifth edition of their annual State of Health Insurance Report. Individual and corporate clients can discover key trends influencing the international private medical insurance (IPMI) sector, such as health inequality, the growth of telemedicine services, the need to … [Read more…]

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics’ U.S. patents 9,593,066 (the ’066 patent) and 10,716,793 (the ’793 patent). This litigation concerns whether … [Read more…]

Hevolution Commits $2 Million in Matching Funds to Support 14 Grants RIYADH, Saudi Arabia–(BUSINESS WIRE)–#agingresearch—Hevolution Foundation, a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science announces the results of $2 Million in matching funding for a program from Impetus Grants, a non-profit science funding organization focused on … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–$DXCM #CGM—DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the promotion of Jake Leach to the role of chief operating officer. Leach has most recently served as chief technology officer at Dexcom since 2018, leading the organization’s research, product development, project management and … [Read more…]

– IPX203 is a novel, extended-release oral formulation of carbidopa and levodopa that if approved, would offer patients more “Good On” time with fewer doses BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Citigroup … [Read more…]

SANTA CLARA, Calif.–(BUSINESS WIRE)–Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conference: Scott Seidelmann, Omnicell Executive Vice President, Chief Commercial Officer, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 1:55p.m. Eastern … [Read more…]

Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MUNICH–(BUSINESS WIRE)–MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Malte Peters, M.D., the company’s Chief Research and Development Officer and Management Board member, has decided to retire at the end of 2022. His … [Read more…]

Arcturus will expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform with the support of the Biomedical Advanced Research and Development Authority $63.2 Million base award to fund development from preclinical stage through Phase 1 over three-year period A lower-dose, freeze-dried, pandemic influenza … [Read more…]